[1] EINTRACHT J,FORSYTHE E,MAY-SIMERA H,et al.Translational readthrough of ciliopathy genes BBS2 and ALMS1 restores protein,ciliogenesis and function in patient fibroblasts[J].E Bio Medicine,2021,70:103515.
[2] SHAHID R K,AHMED S,LE D,et al.Diabetes and cancer:risk,challenges,management and outcomes[J].Cancers(Basel),2021,13(22):5735.
[3] DUAN W,SHEN X,LEI J,et al.Hyperglycemia,a neglected factor during cancer progression[J].Bio Med Research International,2014,2014:461917.
[4] PULIANI G,APPETECCHIA M.Endocrine toxicities of antineoplastic therapy[J].Cancers(Basel),2021,13(2):294.
[5] SINGH S,EARLE C C,BAE S J,et al.Incidence of diabetes in colorectal cancer survivors[J].Journal of the National Cancer Institute,2016,108(6):djv402.
[6] DE BRUIJN K M,VAN EIJCK C H.New-onset diabetes after distal pancreatectomy:a systematic review[J].Ann Surg,2015,261(5):854-861.
[7] YESHAYAHU Y,KOLTIN D,HAMILTON J,et al.Medication-induced diabetes during induction treatment for all,an early marker for future metabolic risk?[J].Pediatric Diabetes,2015,16(2):104-108.
[8] HWANGBO Y,LEE E K.Acute hyperglycemia associated with anti-cancer medication[J].Endocrinology and Metabolism(Seoul,Korea),2017,32(1):23-29.
[9] YOO K E,KANG R Y,LEE J Y,et al.Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy[J].Supportive Care in Cancer,2015,23(7):1969-1977.
[10] LIPSCOMBE L L,CHAN W W,YUN L,et al.Incidence of diabetes among postmenopausal breast cancer survivors[J].Diabetologia,2013,56(3):476-483.
[11] HWANGBO Y,KANG D,KANG M,et al.Incidence of diabetes after cancer development:a Korean national cohort study[J].JAMA Oncology,2018,4(8):1099-1105.
[12] XU K Y,SHAMEEM R,WU S.Risk of hyperglycemia attributable to everolimus in cancer patients:a meta-analysis[J].Acta Oncologica(Stockholm,Sweden),2016,55(9-10):1196-1203.
[13] OEFFINGER K C,ADAMS-HUET B,VICTOR R G,et al.Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia[J].Journal of Clinical Oncology,2009,27(22):3698-3704.
[14] 索珊珊.血液系统肿瘤化疗继发糖尿病临床研究 [D].杭州：浙江大学，2015.
[15] LEE S Y,KURITA N,YOKOYAMA Y,et al.Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy[J].Supportive Care in Cancer,2014,22(5):1385-1390.
[16] MOHN A,Di MARZIO A,CAPANNA R,et al.Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia[J].Lancet(London,England),2004,363(9403):127-128.
[17] MOHN A,DI MARZIO D,DE BERARDINIIS A,et al.Long-term follow-up of children treated for acute lymphoblastic leukemia and the recovery of beta-cell function[J].Haematologica,2006,91(10):1424-1425.
[18] YOSHIDA H,IMAMURA T,SAITO A M,et al.Protracted administration of L-Asparaginase in maintenance phase is the risk factor for hyperglycemia in older patients with pediatric acute lymphoblastic leukemia[J].PLoS One,2015,10(8):e0136428.
[19] GLLO M,MUSCOGIURI G,FELICETTI F,et al.Adverse glycaemic effects of cancer therapy:indications for a rational approach to cancer patients with diabetes[J].Metabolism:Clinical and Experimental,2018,78:141-154.
[20] MATSUURA N,KOH G,KONISHIC,et al.Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC[J].Cancer Immunology,Immunotherapy:CII,2018,67(9):1417-1424.
[21] J HUGHES J,VUDATTU N,SZNOL M,et al.Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy[J].Diabetes Care,2015,38(4):e55-e57.
[22] HWANG J L,WEISS R E.Steroid-induced diabetes:a clinical and molecular approach to understanding and treatment[J].Diabetes/Metabolism Research and Reviews,2014,30(2):96-102.
[23] ARIAANS G,DE JONG S,GIETEMA J A,et al.Cancer-drug induced insulin resistance:innocent bystander or unusual suspect[J].Cancer Treat Rev,2015,41(4):376-384.
[24] DOI T,FUJIWARA Y,MATSUBARA N,et al.Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors[J].Cancer Chemother Pharmacol,2019,84(2):393-404.
[25] ARGILESJ M,BUSQUETS S,STEMMLER B,et al.Cancer cachexia:understanding the molecular basis[J].Nature Reviews Cancer,2014,14(11):754-762.
[26] HONORS M A,KINZIG K P.The role of insulin resistance in the development of muscle wasting during cancer cachexia[J].Journal of Cachexia,Sarcopenia and Muscle,2012,3(1):5-11.
[27] PORPORATO P E.Understanding cachexia as a cancer metabolism syndrome[J].Oncogenesis,2016,5:e200.
[28] KERO A E,JARVELA L S,AROLA M,et al.Late mortality among 5-year survivors of early onset cancer:a population-based register study[J].International Journal of Cancer,2015,136(7):1655-1664.
[29] LEE W,YOON Y S,HAN H S,et al.Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma[J].Journal of Surgical Oncology,2016,113(2):203-208.
[30] CHENG A Y.Canadian diabetes association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada.Introduction[J].Canadian Journal of Diabetes,2013,37(Suppl 1):S1-S3.
[31] OSE D J,VISKOCHIL R,HOLOWATYJ A N,et al.Understanding the prevalence of prediabetes and diabetes in patients with cancer in clinical practice:a real-world cohort study[J].J Natl Compr Canc Netw,2021,19(6):709-718.
[32] American Diabetes Association.Standards of medical care in diabetes-2017:summary of revisions[J].Diabetes Care,2017,40(Suppl 1):S4-S5. |
